Barrington analyst Michael Petusky maintained an Outperform rating and $5 price target on Opko Health after the company reported revenue that slightly exceeded the firm's estimate. However, the analyst noted that "despite an increase in prescriptions of 121% in Q1 versus the same period a year ago, Rayaldee revenue fell short in the quarter and guidance for Q2 revenue was also disappointing." While Petusky noted that there have been "more setbacks than positive surprises" over the last few years, he believes "the company still has many 'shots on goal' within both its current commercial portfolio as well as its product development pipeline."